Target |
Mechanism BTX inhibitors [+1] |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunostimulants |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunostimulants |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date15 Jul 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
NTM-1634 ( BTX ) | Botulism More | Pending |
H5N1 influenza virus vaccine intranasal (National Resilience) | Influenza, Human More | Pending |
Ross River virus vaccine (National Resilience) | Alphavirus Infections More | Pending |
Influenza A virus H9N2 vaccine (National Resilience) | Influenza A virus infection More | Pending |